Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP-1929 PIT + Anti-PD1 in Advanced Solid Tumors
NCT04305795Phase 2Active, not recruiting
- Sponsor
- Rakuten Medical, Inc.
- Start
- Dec 2020
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab sarotalocan sodium in head and neck squamous cell carcinoma (HNSCC), cutaneous squamous cell carcinoma (cSCC), sponsored by Rakuten Medical, Inc.. Started Dec 2020; status: active, not recruiting.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
head and neck squamous cell carcinoma (HNSCC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04305795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305795.